<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360386</url>
  </required_header>
  <id_info>
    <org_study_id>C_9108</org_study_id>
    <nct_id>NCT00360386</nct_id>
  </id_info>
  <brief_title>ALBION &quot;Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis&quot;</brief_title>
  <official_title>Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      -  To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and&#xD;
           platelet activation (flow cytometry) with different loading doses of clopidogrel&#xD;
&#xD;
        -  To evaluate the effect on various parameters of inflammation and necrosis and the safety&#xD;
           of these loading doses&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum intensity of platelet aggregation induced by ADP 5 Âµmol/L.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic profile by aggregometry. Kinetic profile of platelet activation by flow cytometry - Inflammation parameters/markers of necrosis. Death, myocardial infarction, ischemic recurrences leading to revascularisation and/or rehospitalisation.Safety.</measure>
  </secondary_outcome>
  <enrollment>110</enrollment>
  <condition>Ischemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient hospitalised with ischemic symptoms (onset &lt; 48 hours) and at least one of the&#xD;
             following characteristics of NSTEMI:&#xD;
&#xD;
               -  ECG ST or T changes&#xD;
&#xD;
               -  positive troponin&#xD;
&#xD;
          2. Patient treated on admission with 250-500 mg aspirin (oral or IV) and who will receive&#xD;
             low dose aspirin (&lt; or = 100 mg daily) from the next day on&#xD;
&#xD;
          3. Patient treated with bid LMWH (indicated dosage for this indication)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Catheterization scheduled within 24 hours after randomisation&#xD;
&#xD;
          2. Patient presenting an absolute contra-indication to the use of clopidogrel and/or ASA:&#xD;
&#xD;
             - history of drug allergy to thienopyridine derivatives or ASA&#xD;
&#xD;
          3. Severe uncontrolled hypertension (BP &gt; 180 / 100 despite therapy)&#xD;
&#xD;
          4. Platelet count &lt; 100 000 / mm3&#xD;
&#xD;
          5. Neutrophil count &lt; 1800 / mm3&#xD;
&#xD;
          6. Patient with increased risk of bleeding, such as severe hepatic insufficiency, current&#xD;
             peptic ulceration, proliferative diabetic retinopathy&#xD;
&#xD;
          7. History of severe systemic bleeding&#xD;
&#xD;
          8. Patient with any contraindication to LMWH&#xD;
&#xD;
          9. Patient treated with clopidogrel within the last 10 days&#xD;
&#xD;
         10. Patient treated with oral anticoagulants or hirudin or planned to receive these&#xD;
             products during the hospitalisation period&#xD;
&#xD;
         11. Patient treated with ticlopidine, dipyridamol, NSAIDs (including Cox1 and Cox2&#xD;
             inhibitors), cilostazol, GPIIb IIIa antagonists or planned to receive any of these&#xD;
             products within the next 24 hours following randomisation.&#xD;
&#xD;
         12. Patient whose arm venous status is incompatible with an indwelling catheter&#xD;
&#xD;
         13. Patient presenting an evolving cancer&#xD;
&#xD;
         14. Patient with NYHA class IV heart failure&#xD;
&#xD;
         15. Intubated and ventilated patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SAGNARD Luc</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <results_reference>
    <citation>Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006 Sep 5;48(5):931-8. Epub 2006 Aug 17.</citation>
    <PMID>16949482</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <last_update_submitted>August 30, 2010</last_update_submitted>
  <last_update_submitted_qc>August 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

